Cambridge Investment Research Advisors, Inc. Gilead Sciences, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 135,868 shares of GILD stock, worth $12.2 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
135,868
Previous 178,323
23.81%
Holding current value
$12.2 Million
Previous $12.2 Million
6.9%
% of portfolio
0.04%
Previous 0.05%
Shares
31 transactions
Others Institutions Holding GILD
# of Institutions
1,931Shares Held
991MCall Options Held
10.5MPut Options Held
9.75M-
Black Rock Inc. New York, NY121MShares$10.8 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.4 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$6.88 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.55 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.41 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $113B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...